Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.24
INCY's Cash-to-Debt is ranked lower than
77% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. INCY: 1.24 )
Ranked among companies with meaningful Cash-to-Debt only.
INCY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5  Med: 1.19 Max: No Debt
Current: 1.24
Equity-to-Asset 0.26
INCY's Equity-to-Asset is ranked lower than
85% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: 0.26 )
Ranked among companies with meaningful Equity-to-Asset only.
INCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.95  Med: 0.05 Max: 0.78
Current: 0.26
-0.95
0.78
Interest Coverage 3.74
INCY's Interest Coverage is ranked lower than
93% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INCY: 3.74 )
Ranked among companies with meaningful Interest Coverage only.
INCY' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 0.72 Max: 3.74
Current: 3.74
0.02
3.74
Piotroski F-Score: 6
Altman Z-Score: 11.30
Beneish M-Score: -1.51
WACC vs ROIC
14.72%
70.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 13.11
INCY's Operating Margin % is ranked higher than
82% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. INCY: 13.11 )
Ranked among companies with meaningful Operating Margin % only.
INCY' s Operating Margin % Range Over the Past 10 Years
Min: -4064.53  Med: -2.74 Max: 13.11
Current: 13.11
-4064.53
13.11
Net Margin % 9.43
INCY's Net Margin % is ranked higher than
81% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. INCY: 9.43 )
Ranked among companies with meaningful Net Margin % only.
INCY' s Net Margin % Range Over the Past 10 Years
Min: -4565.45  Med: -21.09 Max: 9.43
Current: 9.43
-4565.45
9.43
ROE % 35.08
INCY's ROE % is ranked higher than
96% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. INCY: 35.08 )
Ranked among companies with meaningful ROE % only.
INCY' s ROE % Range Over the Past 10 Years
Min: 14.59  Med: 24.94 Max: 35.29
Current: 35.08
14.59
35.29
ROA % 7.76
INCY's ROA % is ranked higher than
89% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. INCY: 7.76 )
Ranked among companies with meaningful ROA % only.
INCY' s ROA % Range Over the Past 10 Years
Min: -70.43  Med: -15.38 Max: 7.88
Current: 7.76
-70.43
7.88
ROC (Joel Greenblatt) % 114.76
INCY's ROC (Joel Greenblatt) % is ranked higher than
95% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. INCY: 114.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INCY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4727.38  Med: -134.72 Max: 115.22
Current: 114.76
-4727.38
115.22
3-Year Revenue Growth Rate 33.50
INCY's 3-Year Revenue Growth Rate is ranked higher than
84% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. INCY: 33.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INCY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.4  Med: 19.6 Max: 194.1
Current: 33.5
-61.4
194.1
GuruFocus has detected 4 Warning Signs with Incyte Corp $INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INCY Guru Trades in Q1 2016

Jim Simons 304,000 sh (New)
Joel Greenblatt 52,500 sh (New)
Paul Tudor Jones 77,400 sh (+809.20%)
Vanguard Health Care Fund 16,227,748 sh (+68.76%)
Ken Fisher 14,839 sh (+0.14%)
George Soros Sold Out
Frank Sands 3,819,401 sh (-13.61%)
Eaton Vance Worldwide Health Sciences Fund 429,400 sh (-0.49%)
» More
Q2 2016

INCY Guru Trades in Q2 2016

George Soros 7,500 sh (New)
Joel Greenblatt 142,607 sh (+171.63%)
Frank Sands 4,467,286 sh (+16.96%)
Paul Tudor Jones 81,409 sh (+5.18%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Ken Fisher 14,818 sh (-0.14%)
Jim Simons 164,567 sh (-45.87%)
Eaton Vance Worldwide Health Sciences Fund 363,900 sh (-15.25%)
» More
Q3 2016

INCY Guru Trades in Q3 2016

John Burbank 243,396 sh (New)
Steven Cohen 68,000 sh (New)
Jana Partners 58,385 sh (New)
Pioneer Investments 80,822 sh (New)
Andreas Halvorsen 503,645 sh (New)
Ken Fisher 14,917 sh (+0.67%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Frank Sands 4,124,074 sh (-7.68%)
Joel Greenblatt 108,099 sh (-24.20%)
George Soros 5,200 sh (-30.67%)
Jim Simons 62,900 sh (-61.78%)
Paul Tudor Jones 10,933 sh (-86.57%)
Eaton Vance Worldwide Health Sciences Fund 237,999 sh (-34.60%)
» More
Q4 2016

INCY Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 91,970 sh (New)
Pioneer Investments 623,117 sh (+670.97%)
Steven Cohen 438,801 sh (+545.30%)
Jana Partners 86,616 sh (+48.35%)
Andreas Halvorsen 730,452 sh (+45.03%)
Ken Fisher 14,917 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Frank Sands 3,652,652 sh (-11.43%)
Vanguard Health Care Fund 11,635,908 sh (-28.30%)
Joel Greenblatt 59,202 sh (-45.23%)
Paul Tudor Jones 4,203 sh (-61.56%)
John Burbank 63,593 sh (-73.87%)
Eaton Vance Worldwide Health Sciences Fund 228,436 sh (-4.02%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:ALIOY, NAS:VRTX, NAS:ALXN, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, OTCPK:GMXAY, NAS:REGN, OTCPK:NVZMF, NAS:SGEN, OTCPK:CSLLY, NAS:JAZZ, NAS:ALKS, NAS:UTHR, NAS:EXEL, NAS:IONS, NAS:ACAD, NAS:ARIA, NAS:ALNY, NAS:TECH » details
Traded in other countries:ICY.Germany,
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.

Top Ranked Articles about Incyte Corp

Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Viking Global adds to biotech holdings with 7.8% of shares
Andreas Halvorsen (Trades, Portfolio)’s $30 billion Viking Global hedge fund has invested in a new class of cancer drugs being developed by Calithera Biosciences Inc. (NASDAQ:CALA), it announced on Tuesday evening, via a stake worth 7.8% of its shares. Read more...
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions Solid growth has attended the sector until this year
Against a backdrop of solid growth for the sector, the outperforming Vanguard Health Care Fund (Trades, Portfolio) replenished its portfolio in the first quarter with increases in 27 holdings and reductions or removal of 28 holdings. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...

Ratios

vs
industry
vs
history
PE Ratio 247.55
INCY's PE Ratio is ranked lower than
95% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. INCY: 247.55 )
Ranked among companies with meaningful PE Ratio only.
INCY' s PE Ratio Range Over the Past 10 Years
Min: 100.16  Med: 260.28 Max: 5661.5
Current: 247.55
100.16
5661.5
Forward PE Ratio 95.24
INCY's Forward PE Ratio is ranked lower than
96% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. INCY: 95.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 247.55
INCY's PE Ratio without NRI is ranked lower than
94% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. INCY: 247.55 )
Ranked among companies with meaningful PE Ratio without NRI only.
INCY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 100.16  Med: 260.28 Max: 5661.5
Current: 247.55
100.16
5661.5
Price-to-Owner-Earnings 162.58
INCY's Price-to-Owner-Earnings is ranked lower than
85% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. INCY: 162.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INCY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.73  Med: 119.3 Max: 3235.14
Current: 162.58
10.73
3235.14
PB Ratio 59.09
INCY's PB Ratio is ranked lower than
98% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. INCY: 59.09 )
Ranked among companies with meaningful PB Ratio only.
INCY' s PB Ratio Range Over the Past 10 Years
Min: 40.27  Med: 74.55 Max: 391.93
Current: 59.09
40.27
391.93
PS Ratio 22.99
INCY's PS Ratio is ranked lower than
60% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. INCY: 22.99 )
Ranked among companies with meaningful PS Ratio only.
INCY' s PS Ratio Range Over the Past 10 Years
Min: 7.13  Med: 21.28 Max: 239.71
Current: 22.99
7.13
239.71
Price-to-Free-Cash-Flow 137.96
INCY's Price-to-Free-Cash-Flow is ranked lower than
87% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. INCY: 137.96 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INCY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.56  Med: 135.93 Max: 1176.61
Current: 137.96
6.56
1176.61
Price-to-Operating-Cash-Flow 83.42
INCY's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. INCY: 83.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INCY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.52  Med: 83.23 Max: 775.18
Current: 83.42
6.52
775.18
EV-to-EBIT 169.00
INCY's EV-to-EBIT is ranked lower than
95% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. INCY: 169.00 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8436.1  Med: -8.5 Max: 1546.6
Current: 169
-8436.1
1546.6
EV-to-EBITDA 120.71
INCY's EV-to-EBITDA is ranked lower than
91% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. INCY: 120.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -662.5  Med: -6.5 Max: 2618.5
Current: 120.71
-662.5
2618.5
Current Ratio 3.64
INCY's Current Ratio is ranked lower than
55% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. INCY: 3.64 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 2.13  Med: 4.98 Max: 15.29
Current: 3.64
2.13
15.29
Quick Ratio 3.62
INCY's Quick Ratio is ranked lower than
53% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. INCY: 3.62 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 2.13  Med: 4.97 Max: 15.29
Current: 3.62
2.13
15.29
Days Inventory 21.83
INCY's Days Inventory is ranked higher than
87% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. INCY: 21.83 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 46.41 Max: 323.15
Current: 21.83
14.49
323.15
Days Sales Outstanding 49.11
INCY's Days Sales Outstanding is ranked higher than
61% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. INCY: 49.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 45.23 Max: 6447.52
Current: 49.11
12.25
6447.52
Days Payable 474.22
INCY's Days Payable is ranked higher than
94% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. INCY: 474.22 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 407.13  Med: 2972.25 Max: 32457.1
Current: 474.22
407.13
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
INCY's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. INCY: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.4  Med: -7.5 Max: -0.6
Current: -5
-13.4
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 85.20
INCY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
95% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. INCY: 85.20 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INCY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 51.83  Med: 58.47 Max: 85.55
Current: 85.2
51.83
85.55
Price-to-Median-PS-Value 1.08
INCY's Price-to-Median-PS-Value is ranked lower than
52% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. INCY: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INCY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.83 Max: 4.65
Current: 1.08
0.15
4.65
Earnings Yield (Greenblatt) % 0.58
INCY's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. INCY: 0.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INCY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.65 Max: 1.3
Current: 0.58
0.1
1.3

More Statistics

Revenue (TTM) (Mil) $1,106
EPS (TTM) $ 0.53
Beta1.67
Short Percentage of Float4.08%
52-Week Range $60.30 - 131.89
Shares Outstanding (Mil)189.41

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,545 1,702 2,097
EPS ($) 1.35 1.56 2.91
EPS without NRI ($) 1.35 1.56 2.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
169.29%
Dividends per Share ($)
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Feb 22 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
Top Insider Trades of the Past Week Feb 19 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 

More From Other Websites
Pharma company Incyte is moving to the S&P 500, and the stock is rallying Feb 24 2017
Incyte, University of Pennsylvania In Cancer Deal Feb 24 2017
Biotech Movers: Cempra Flys High On Phase Three Results Feb 24 2017
Incyte, CBOE Holdings, Regency Centers Set to Join S&P 500; Others to Join S&P MidCap 400 Feb 23 2017
Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of... Feb 23 2017
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Feb 22 2017
Incyte to Present at Upcoming Investor Conferences Feb 21 2017
INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Feb 21 2017
INCYTE CORP Financials Feb 18 2017
Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market Feb 17 2017
NetEase Delivers Nice Option Win; Mobileye, Tesla, InterDigital On Deck Feb 17 2017
Incyte Corp. :INCY-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show... Feb 15 2017
Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show... Feb 15 2017
Softness in Incyte Should Be Short-Lived, if Our Quants Are Right Feb 15 2017
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook Feb 15 2017
Incyte Corp. :INCY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Feb 15 2017
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data Feb 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)